This Is How the CRISPR Trial Will Determine Our Future


Bild: 4ever.eu
Bild: 4ever.eu
Arguments in a trial to determine ownership of CRISPR, a gene editing technology, started Tuesday in Virginia. The outcome will determine who gets ownership of an incredibly lucrative and incredibly powerful tool that has the potential to “treat” genetic disease.

By Meredith Rutland Bauer | MOTHERBOARD

Arguments in a trial to determine ownership of CRISPR, a gene editing technology, started Tuesday in Virginia. The outcome will determine who gets ownership of an incredibly lucrative and incredibly powerful tool that has the potential to “treat” genetic disease.

Two groups are contending for the editing technology patent: on one side is MIT’s Broad Institute and Harvard University, and on the other is the University of California, Berkeley.

The first patent for this technology was filed in 2012 by University of California, Berkeley, researchers for their work describing how genes could be edited in-vitro, The Scientist reported. Later in 2012, researchers at Harvard and MIT filed a patent for editing genes in eukaryotic cells—like those in a forming baby. The UC Berkeley researchers claimed the second patent violated their patent, and this week’s trial will determine who gets intellectual rights to the technology.

read more